All In Biotech

Drug Trial Radar · NCT03711032

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,397 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,397

Planned (sponsor's estimate)

Start

Dec 24, 2018

Primary completion

Jul 31, 2028

Study completion Nov 20, 2034

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. The goals of this study are to learn: 1. If more people who receive pembrolizumab with Bacillus Calmette-Guerin (BCG) have no signs of cancer in their body and live longer without the cancer growing, spreading, or coming back compared to people who receive BCG alone. 2. About the safety and how well people tolerate BCG alone or in combination with pembrolizumab.

Conditions

  • High-risk Non-muscle Invasive Bladder Cancer

Interventions

  • PembrolizumabBiological

    Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization

  • BCGBiological

    BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A)Time frame: Up to ~3.5 years
  2. Event-Free Survival (EFS) (Cohort B)Time frame: Up to ~5 years

Locations

209 sites in 30 countries. Site status is shown where the registry gives one.

  • Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083)

    Anchorage, Alaska

  • Mayo Clinic in Arizona - Phoenix ( Site 1094)

    Phoenix, Arizona

  • Del Sol Research Management, LLC ( Site 1096)

    Tucson, Arizona

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 1052)

    Los Angeles, California

  • University of California Irvine Medical Center ( Site 1061)

    Orange, California

  • Genesis Research LLC ( Site 1065)

    Torrance, California

  • Colorado Clinical Research ( Site 1100)

    Lakewood, Colorado

  • Urological Research Network ( Site 1106)

    Hialeah, Florida

  • Mayo Clinic in Florida-Urology ( Site 1097)

    Jacksonville, Florida

  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1056)

    Miami, Florida

  • Woodlands Medical Specialists, PA ( Site 8002)

    Pensacola, Florida

  • Emory School of Medicine ( Site 1076)

    Atlanta, Georgia

  • Advanced Urology ( Site 1092)

    Roswell, Georgia

  • Northwestern Memorial Hospital ( Site 1101)

    Chicago, Illinois

  • Wichita Urology Group ( Site 1086)

    Wichita, Kansas

  • Ochsner LSU Health Shreveport - Regional Urology ( Site 1099)

    Shreveport, Louisiana

  • Henry Ford Hospital ( Site 1062)

    Detroit, Michigan

  • Michigan Institute of Urology ( Site 1077)

    Troy, Michigan

  • Coastal Urology Associates ( Site 1055)

    Brick, New Jersey

  • Morristown Medical Center ( Site 1090)

    Morristown, New Jersey

  • Rutgers Cancer Institute of New Jersey ( Site 1059)

    New Brunswick, New Jersey

  • St. Peter's Hospital Cancer Care Center ( Site 1087)

    Albany, New York

  • R.J. Zuckerberg Cancer Center ( Site 1080)

    Lake Success, New York

  • Veterans Affairs New York Harbor Healthcare System-PCF COE ( Site 1112)

    New York, New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 1074)

    New York, New York

  • Associated Medical Professionals of NY ( Site 1078)

    Syracuse, New York

  • TriState Urologic Services PSC Inc. dba The Urology Group ( Site 1091)

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center ( Site 1066)

    Cleveland, Ohio

  • Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 1067)

    Columbus, Ohio

  • OHSU Knight Cancer Institute ( Site 1075)

    Portland, Oregon

  • Oregon Urology Institute ( Site 1098)

    Springfield, Oregon

  • MidLantic Urology ( Site 1071)

    Bala-Cynwyd, Pennsylvania

  • Lancaster Urology ( Site 1079)

    Lancaster, Pennsylvania

  • University of Pennsylvania ( Site 1088)

    Philadelphia, Pennsylvania

  • Carolina Urologic Research Center ( Site 1085)

    Myrtle Beach, South Carolina

  • Urology Associates [Nashville, TN] ( Site 1072)

    Nashville, Tennessee

  • Urology Clinics of North Texas, PLLC ( Site 1064)

    Dallas, Texas

  • University Of Texas Southwestern Medical Center ( Site 1053)

    Dallas, Texas

  • Texas Oncology-Fort Worth Cancer Center ( Site 8003)

    Fort Worth, Texas

  • Houston Metro Urology ( Site 1111)

    Houston, Texas

Showing 40 of 209 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.